Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 35 clinical trials
featured
A 24-week, double-blind, randomized, parallel-group study evaluating the efficacy and safety of oral nintedanib coadministered with oral sildenafil, compared to treatment with nintedanib alone, in patients with idiopathic pulmonary fibrosis (IPF) and advanced lung function impairment

A 24-week, double-blind, randomized, parallel-group study evaluating the efficacy and safety of oral nintedanib coadministered with oral sildenafil, compared to treatment with nintedanib alone, in

  • 1316 views
  • 23 Nov, 2020
  • 1 location
Efficacy of Nintedanib Per os as a Treatment for Epistaxis in HHT Disease.

kinase inhibitors are anti-angiogenic molecules which are available orally and could therefore overcome the difficulties encountered with bevacizumab. The investigator hypothesized that nintedanib

  • 0 views
  • 27 Jan, 2021
  • 10 locations
Management of Progressive Disease in Idiopathic Pulmonary Fibrosis

-modifying therapies, pirfenidone and nintedanib, have been approved worldwide. Both drugs reduce the disease progression as measured by progressive decline in forced vital capacity (FVC), with a reduction

  • 0 views
  • 09 May, 2021
  • 1 location
A Study to Find Out How Nintedanib is Taken up in the Body and How Well it is Tolerated in Children and Adolescents With Interstitial Lung Disease (ILD).

The main objective of the study is to evaluate dose-exposure and safety of nintedanib in children and adolescents with fibrosing Interstitial Lung Disease (ILD).

fibrosis
nintedanib
pulmonary disease
  • 7 views
  • 12 May, 2021
  • 61 locations
A Study to Test the Efficacy and Safety of Inhaled TD139 in Subjects With Idiopathic Pulmonary Fibrosis (IPF)

This is a randomized, double-blind, placebo-controlled phase 2b trial in subjects with IPF (idiopathic pulmonary fibrosis) investigating the efficacy and safety of TD139.

idiopathic pulmonary fibrosis
pirfenidone
forced vital capacity
carbon monoxide
diffusion capacity of the lung for carbon monoxide
  • 384 views
  • 15 Feb, 2021
  • 132 locations
Evaluation of Efficacy and Safety of Pamrevlumab in Patients With Idiopathic Pulmonary Fibrosis

This is a Phase 3 trial to evaluate the efficacy and safety of 30 mg/kg intravenous (IV) infusions of pamrevlumab administered every 3 weeks as compared to placebo in subjects with Idiopathic Pulmonary Fibrosis

idiopathic pulmonary fibrosis
pirfenidone
carbon monoxide
diffusion capacity of the lung for carbon monoxide
pamrevlumab
  • 349 views
  • 02 Feb, 2021
  • 67 locations
Zephyrus II: Efficacy and Safety Study of Pamrevlumab in Subjects With Idiopathic Pulmonary Fibrosis (IPF)

This is a Phase 3 trial to evaluate the efficacy and safety of 30 mg/kg intravenous (IV) infusions of pamrevlumab administered every 3 weeks as compared to placebo in subjects with Idiopathic Pulmonary Fibrosis

idiopathic pulmonary fibrosis
pirfenidone
carbon monoxide
diffusion capacity of the lung for carbon monoxide
pamrevlumab
  • 0 views
  • 03 Feb, 2021
  • 10 locations
Trial Of Pembrolizumab And Nintedanib

Both anti-angiogenesis and anti PD1 immunotherapy have shown beneficial efficacy in solid tumors and in particular in NSCLC. Therefore it is of interest to investigate whether the combination of these two approaches is tolerable. Moreover, comprehensive pre-clinical and clinical rationale sustain the hypothesis that anti-VEGF could synergize with immunotherapy for …

  • 0 views
  • 24 Jan, 2021
  • 1 location
Study of Nintedanib and Chemotherapy for Advanced Pancreatic Cancer

The study will perform a clinical study evaluating the safety and tolerability of nintedanib when combined with standard chemotherapy (Gemcitabine + nab-Paclitaxel) for metastatic pancreatic

paclitaxel
gemcitabine
metastatic pancreatic cancer
drainage
adenocarcinoma
  • 16 views
  • 25 Jan, 2021
  • 1 location
Continuation of Nintedanib After Single Lung Transplantation in IPF Subjects

The aim of this study is to assess the utility of nintedanib therapy in addition to usual transplant care in single lung transplant recipients with idiopathic pulmonary fibrosis (IPF). The

pulmonary function test
ofev
idiopathic pulmonary fibrosis
bibf 1120
nintedanib
  • 57 views
  • 23 Jan, 2021
  • 1 location